Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the ESMO Congress 2023.

The Autumn Newsletter has arrived with updates on a range of GIST-related matters.  GIST Cancer UK October Newsletter

Videos of the sessions at the October 2023 Patient Carer meeting held in Leeds are now available on the Patient Meetings 2023 section of this site.

The outcome of the recent Intrigue study which compared the effectiveness and side effects associated with these drugs can be found here

The Life Raft. Group (the US equivalent of GIST Cancer UK) hold a series of online events that may be of interest to patients and carers in the UK.  The next one is on September 18th and is entitled: Managing the side-effects of GIST therapies.

The Board of Trustees continue to look at how the charity operates in order to keep costs low and bureaucracy to a minimum. Following a review of our financial structure, we are reducing the number of bank accounts we have and instead starting to utilise facilities that attract bank interest. To facilitate this, we ask […]

The annual Scottish patient meeting will take place on Friday, 1st December 2023 at the Cosla Conference Centre, Verity House, 19 Haymarket Yards,  Edinburgh EJ12 5BH.  To book a place please email meetings@gistcancer.org.uk

The May edition of our new newsletter is now available and can be downloaded here.  GIST Cancer UK May Newsletter

Video recordings from the recent London Patient/Carer event are now available under the ‘Patient Meetings‘ section of this site.

At the recent BSG Conference, Drs Bulusu and Jennifer Harrington presented findings from an initial exploration of the effectiveness of different generic versions of imatinib,